Published in Health and Medicine Week, April 27th, 2006
Full year 2005 revenues were in line with guidance given during an annual press conference and analyst meeting in March, at EUR 9.6 million, an increase of 21% compared to FY 2004 of EUR 7.9 million. This was mainly due to successfully meeting the Roche program milestone in colon cancer screening and the strong performance of our SBU Clinical Solutions. The 2005 revenue base has been further broadened to include the new partners Qiagen and Philip Morris.
In 2005, Epigenomics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.